We are focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings
Year founded1997
Served areaEurope
HeadquartersWeinbergweg 22, 06120 Halle (Germany) – Netherlands
24,105,278
IPOJan. 1, 2000
Stock exchange(s)Euronext Amsterdam